Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000859583p
Ethics application status
Not yet submitted
Date submitted
19/06/2024
Date registered
12/07/2024
Date last updated
12/07/2024
Date data sharing statement initially provided
12/07/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Establishing Dynamic Immune Biomarkers in Follicular Lymphoma Patients Treated with Bispecific Antibody Therapy
Query!
Scientific title
ALLG LS25: Establishing Dynamic Immune Biomarkers in Follicular Lymphoma Patients Treated with Bispecific Antibody Therapy
Query!
Secondary ID [1]
312284
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ALLG LS25
Query!
Linked study record
This ANZCTR is a sub-study of the study registered under NCT06191744.
Query!
Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma
334007
0
Query!
Condition category
Condition code
Cancer
330681
330681
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Follicular lymphoma (FL) is a common type of slow-growing blood cancer. In Australia, the standard treatment for FL is a combination of drugs and immunotherapy. However, this treatment can have side effects, and the cancer can come back without clear options for further treatment.
The LS25 trial is a translational sub-study to the upcoming EPCORE-FL2 trial sponsored by AbbVie. Patients enrolled to the EPCORE-FL2 trial will be recruited to the LS25 trial and will be consented for 1) the collection of an additional volume of peripheral blood at 5 timepoints 2) self-administration of gastrointestinal microbiota sampling and 3) an ‘on-treatment’ biopsy.
All collection timepoints for the ALLG LS25 trial correspond to those in the EPCORE FL-2 clinical trial at:
1. baseline
2. cycle 1 day 15
3. on-treatment biopsy window between cycle 1 day 23 – cycle 2 day 8
4. 24 weeks
5. 120 weeks.
There are no additional collection timepoints outside of the clinical trial protocol.
Query!
Intervention code [1]
328749
0
Not applicable
Query!
Comparator / control treatment
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
338439
0
To assess whether baseline and dynamic measures of poor immune fitness are predictive of early progression of disease (ePOD) events in Follicular Lymphoma (FL) patients (As a composite primary outcome).
Query!
Assessment method [1]
338439
0
Peripheral blood (PB) tests for DNA and RNA Sequencing, Proteomics & Functional Cell Culture Modelling
Tissue biopsies for DNA and RNA Sequencing, spatial transcriptomics & Proteomics.
Self-administered microbiome swab sampling for Gastrointestinal Microbiome Sequencing.
Query!
Timepoint [1]
338439
0
PB at baseline, cycle 1 day 15, between cycle 1 day 23 – cycle 2 day 8, 24 weeks and 120 weeks post baseline.
Optional tissue biopsy at baseline and within the "on-treatment" biopsy collection window (between cycle 1 day 23 – cycle 2 day 8).
Microbiome swab at baseline, 24 weeks and 120 weeks post baseline.
Query!
Secondary outcome [1]
435953
0
Nil
Query!
Assessment method [1]
435953
0
Nil
Query!
Timepoint [1]
435953
0
Nil
Query!
Eligibility
Key inclusion criteria
Patients at who are participating in the Abbvie sponsored clinical trial titled ‘A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab and Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE FL-2)’ are eligible to partake in the ALLG LS25 study.
1. Diagnosis of follicular lymphoma (FL).
2. Have CD20, histologically confirmed classic FL (previously Grade 1 to 3a FL) at most recent representative tumor biopsy based on the local pathology report, according to the 5th edition of World Health Organization (WHO) Classification of Haematolymphoid Tumours.
3. Must have stage, III or IV disease, or stage II with bulky disease (tumor diameter of greater than or equal to 7 cm).
4. Must be in need of systemic treatment per investigator, as evidenced by meeting at least one of the Groupe d'Etude des Lymphomes Folliculaire (GELF) criteria.
5. Has one or more target lesions:
a) A positron emission tomography (PET) or computerized tomography (CT) scan demonstrating PET-positive lesion(s), and
b) Have greater than or equal to 1 measurable nodal lesion (long axis greater than 1.5cm) or greater than or equal to 1 measurable extra-nodal lesion (long axis greater than 1.0 cm) on CT scan or MRI
6) Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
7) Eligible to receive one of the standard of care regimens: chemoimmunotherapy (CIT) or rituximab and lenalidomide (R2).
8) Have laboratory values meeting the criteria in the protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1) Had major surgery within 4 weeks prior to randomization.
2) Have active cytomegalovirus (CMV) disease..
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/08/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
50
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC
Query!
Recruitment outside Australia
Country [1]
26363
0
New Zealand
Query!
State/province [1]
26363
0
Query!
Funding & Sponsors
Funding source category [1]
316672
0
Other Collaborative groups
Query!
Name [1]
316672
0
Australasian Leukaemia and Lymphoma Group (ALLG)
Query!
Address [1]
316672
0
Query!
Country [1]
316672
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
Australasian Leukaemia and Lymphoma Group (ALLG)
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
318864
0
None
Query!
Name [1]
318864
0
Nil
Query!
Address [1]
318864
0
Query!
Country [1]
318864
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
315450
0
Metro South Human Research Ethics Committee
Query!
Ethics committee address [1]
315450
0
https://metrosouth.health.qld.gov.au/research/about-us/hrec
Query!
Ethics committee country [1]
315450
0
Australia
Query!
Date submitted for ethics approval [1]
315450
0
15/07/2024
Query!
Approval date [1]
315450
0
Query!
Ethics approval number [1]
315450
0
Query!
Summary
Brief summary
Follicular lymphoma (FL) is a common type of slow-growing blood cancer. In Australia, the standard treatment for FL is a combination of drugs and immunotherapy. However, this treatment can have side effects, and the cancer can come back without clear options for further treatment. Researchers are now focusing on finding better options to treat FL with fewer side effects and better outcomes for patients. Who is it for? You may be eligible for this study if you are aged 18 and have been diagnosed with follicular lymphoma. Study details LS25 will operate as a sub-study of an AbbVie-sponsored clinical trial called EPCORE-FL2, with the aim to closely monitor how the immune system responds to treatment for FL over time. EPCORE-FL2 patients can choose to participate in LS25, where they will provide extra blood samples, biopsy sample and collect gastrointestinal microbiota sampling. These samples will help researchers understand how the immune system is working inside the tumor and in the bloodstream during treatment. The hope is that by studying these samples, treatments can be tailored more effectively for people with FL, potentially leading to better outcomes.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
134742
0
Dr Joshua Tobin
Query!
Address
134742
0
Translational Research Institute, 37 Kent Street, Woolloongabba, Qld 4102
Query!
Country
134742
0
Australia
Query!
Phone
134742
0
+61 7 3365 1234
Query!
Fax
134742
0
Query!
Email
134742
0
[email protected]
Query!
Contact person for public queries
Name
134743
0
Delaine Smith
Query!
Address
134743
0
Australasian Leukaemia & Lymphoma Group, 35 Elizabeth St, Richmond, VIC 3121
Query!
Country
134743
0
Australia
Query!
Phone
134743
0
+61 3 8373 9701
Query!
Fax
134743
0
Query!
Email
134743
0
[email protected]
Query!
Contact person for scientific queries
Name
134744
0
Delaine Smith
Query!
Address
134744
0
Australasian Leukaemia & Lymphoma Group, 35 Elizabeth St, Richmond, VIC 3121
Query!
Country
134744
0
Australia
Query!
Phone
134744
0
+61 3 8373 9701
Query!
Fax
134744
0
Query!
Email
134744
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified IPD data for all data collected during the trial
Query!
When will data be available (start and end dates)?
Data available 3 months following publication, for an indefinite period
Query!
Available to whom?
Data are potentially available to:
• Researchers from not-for-profit organisations
• Commercial organisations
• Other
Based in:
• Any location
Further information:
All data requests will be considered by the primary sponsor on a case by case basis. Requests must include a methodologically sound proposal. Specific conditions of use may apply that the requester must agree to before access is granted
Query!
Available for what types of analyses?
Any type of analysis
Assessed on a case-by-case basis
Query!
How or where can data be obtained?
Access can be requested via the Health Data Australia catalogue (https://researchdata.edu.au/health/). Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to
[email protected]
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
23903
Study protocol
[email protected]
Access can be requested via the Health Data Austra...
[
More Details
]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF